Synta Announces Presentation of Small Cell Lung Cancer Results; Synta's Ganetespib More Potent Than 17-AAG

Synta Pharmaceuticals Corp. SNTA today announced that results presented at the International Association for the Study of Lung Cancer 14th World Conference on Lung Cancer showed that ganetespib is more potent than 17-AAG and is synergistic with doxorubicin in a model of small cell lung cancer. Ganetespib is a potent inhibitor of heat shock protein 90 currently being studied in a broad range of clinical trials with approximately 400 patients treated to date. Ganetespib is structurally unrelated to first-generation, ansamycin-family Hsp90 inhibitors such as 17-AAG or IPI-504.